Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Lexeo Therapeutics Announces In-License Agreement With Cornell University To Expedite Development Of LX2006 For Treatment Of Friedreich Ataxia Cardiomyopathy; Under Agreement, Co. Has Acquired Certain Rights1 Including Rights To Current And Future Data Generated In An Ongoing Investigator-initiated Phase 1A Trial Of AAVrh.10hFXN To Treat Fa Cardiomyopathy

Author: Benzinga Newsdesk | April 22, 2024 07:32am

Posted In: LXEO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist